People with solid tumors often face tough choices about treatment options. A new review of data found that pucotenlimab, a type of immunotherapy, helped patients respond better to treatment compared to control groups. This analysis looked at conditions like gastric cancer, gastroesophageal junction cancer, triple-negative breast cancer, melanoma, and specific solid tumors with dMMR or MSI-H markers.
The data showed clear benefits. Patients receiving the drug had significantly improved outcomes versus control. In triple-negative breast cancer patients treated with gemcitabine and cisplatin, the response rate reached 80.6 percent. For those with mucosal melanoma, the response rate was lower at 8.7 percent. The analysis also found that combining pucotenlimab with other therapies was superior to using the drug alone.
Safety is always a concern. The review noted immune-related adverse events, which are side effects from the immune system. In high-risk groups, these serious side events occurred in 41.2 percent of cases. In lower-risk groups, the rate was much lower at 3.5 percent. This review helps doctors define precise application scenarios and provides an extensible analytical paradigm for future care.